Beyond lung cancer screening, an opportunity for early detection of chronic obstructive pulmonary disease and cardiovascular diseases.

Sébastien Gendarme, Bernard Maitre, Sam Hanash, Jean-Claude Pairon, Florence Canoui-Poitrine, Christos Chouaïd
Author Information
  1. Sébastien Gendarme: Pulmonology Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France. ORCID
  2. Bernard Maitre: Pulmonology Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
  3. Sam Hanash: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  4. Jean-Claude Pairon: Inserm U955, IMRB, Université Paris-Est Créteil, Créteil, France.
  5. Florence Canoui-Poitrine: Inserm U955, IMRB, Université Paris-Est Créteil, Créteil, France.
  6. Christos Chouaïd: Pulmonology Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Abstract

BACKGROUND: Lung cancer screening programs concern smokers at risk for cardiovascular diseases (CVDs) and chronic obstructive pulmonary disease (COPD). The LUMASCAN (LUng Cancer Screening, MArkers and low-dose computed tomography SCANner) study aimed to evaluate the acceptability and feasibility of screening for these 3 diseases in a community population with centralized organization and to determine low-dose computed tomography (CT) markers associated with each disease.
METHODS: This cohort enrolled participants meeting National Comprehensive Cancer Network criteria (v1.2014) in an organized lung cancer-screening program including low-dose CT scans; spirometry; evaluations of coronary artery calcifications (CACs); and a smoking cessation plan at inclusion, 1, and 2 years; then telephone follow-up. Outcomes were the participation rate and the proportion of participants affected by lung cancer, obstructive lung disease, or CVD events. Logistic-regression models were used to identify radiological factors associated with each disease.
RESULTS: Between 2016 and 2019, a total of 302 participants were enrolled: 61% men; median age 58.8 years; 77% active smoker; 11% diabetes; 38% hypertension; and 27% taking lipid-lowering agents. Inclusion, 1-year, and 2-year participation rates were 99%, 81%, 79%, respectively. After a median follow-up of 5.81 years, screenings detected 12 (4%) lung cancer, 9 of 12 via low-dose CT (78% localized) and 3 of 12 during follow-up (all stage IV), 83 (27%) unknown obstructive lung disease, and 131 (43.4%) moderate to severe CACs warranting a cardiology consultation. Preexisting COPD and moderate to severe CACs were associated with major CVD events with odds ratios of 1.98 (95% confident interval [CI] = 1.00 to 3.88) and 3.27 (95% CI = 1.72 to 6.43), respectively.
CONCLUSION: The LUMASCAN study demonstrated the feasibility of combined screening for lung cancer, COPD, and CVD in a community population. Its centralized organization enabled high participation and coordination of healthcare practitioners.

References

  1. N Engl J Med. 2011 Aug 4;365(5):395-409 [PMID: 21714641]
  2. Chest. 2022 Mar;161(3):818-825 [PMID: 34536385]
  3. Eur Heart J Cardiovasc Imaging. 2020 Oct 20;21(11):1216-1224 [PMID: 32584979]
  4. Eur Radiol. 2022 May;32(5):3067-3075 [PMID: 34973103]
  5. Eur Respir J. 2005 Aug;26(2):319-38 [PMID: 16055882]
  6. Clin Lung Cancer. 2022 Jan;23(1):e54-e59 [PMID: 34764039]
  7. Chest. 2022 Jul;162(1):230-241 [PMID: 35149081]
  8. Eur Radiol. 2024 Jul;34(7):4448-4456 [PMID: 38060003]
  9. Thorax. 2019 Dec;74(12):1140-1146 [PMID: 31558626]
  10. Ann Am Thorac Soc. 2019 May;16(5):641-644 [PMID: 30673510]
  11. Thorax. 2020 Aug;75(8):655-660 [PMID: 32444437]
  12. Eur J Epidemiol. 2020 Jan;35(1):75-86 [PMID: 31016436]
  13. Eur Respir J. 2022 May 12;59(5): [PMID: 34649976]
  14. Clin Lung Cancer. 2020 Mar;21(2):145-152 [PMID: 31982356]
  15. Eur Heart J. 2021 Sep 7;42(34):3227-3337 [PMID: 34458905]
  16. Respir Med. 2021 Jan;176:106245 [PMID: 33253972]
  17. Eur Respir J. 2017 Mar 6;49(3): [PMID: 28182564]
  18. Transl Lung Cancer Res. 2021 Feb;10(2):1141-1153 [PMID: 33718052]
  19. J Clin Oncol. 2021 Aug 10;39(23):2574-2585 [PMID: 34236916]
  20. J Thorac Imaging. 2014 Sep;29(5):310-6 [PMID: 24992501]
  21. Thorax. 2019 Jul;74(7):700-704 [PMID: 30420406]
  22. Eur Heart J. 2021 Jul 1;42(25):2439-2454 [PMID: 34120177]
  23. Eur Respir J. 2022 Dec 8;60(6): [PMID: 35896207]
  24. Thorax. 2010 Jul;65(7):600-5 [PMID: 20627916]
  25. Lung Cancer. 2021 Mar;153:21-24 [PMID: 33445120]
  26. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1060-7 [PMID: 26199983]
  27. BMJ. 2017 May 23;357:j2099 [PMID: 28536104]
  28. Radiology. 2015 Jul;276(1):82-90 [PMID: 25759972]
  29. Eur Respir J. 2023 Oct 19;62(4): [PMID: 37802631]
  30. Lung Cancer. 2018 Oct;124:148-153 [PMID: 30268454]
  31. Front Oncol. 2017 Dec 13;7:308 [PMID: 29322029]
  32. Ann Am Thorac Soc. 2020 Jul;17(7):869-878 [PMID: 32164439]
  33. J Thorac Dis. 2018 May;10(5):2740-2751 [PMID: 29997936]
  34. Cochrane Database Syst Rev. 2022 Aug 3;8:CD013829 [PMID: 35921047]
  35. N Engl J Med. 2020 Feb 6;382(6):503-513 [PMID: 31995683]
  36. J Thorac Oncol. 2020 Jul;15(7):1160-1169 [PMID: 32160967]
  37. Chest. 2021 May;159(5):1812-1820 [PMID: 33326807]
  38. Chest. 2023 Feb;163(2):455-463 [PMID: 35932889]
  39. Lancet Oncol. 2023 May;24(5):e207-e218 [PMID: 37142382]
  40. J Natl Cancer Inst. 2014 May 28;106(6):dju084 [PMID: 24872540]
  41. BMC Pulm Med. 2022 Dec 15;22(1):478 [PMID: 36522781]
  42. Eur J Radiol. 2021 Dec;145:110040 [PMID: 34814037]
  43. J Thorac Oncol. 2021 Feb;16(2):228-236 [PMID: 33137463]
  44. Eur Respir J. 2021 Sep 2;58(3): [PMID: 33574075]
  45. BMJ Open. 2022 Dec 26;12(12):e067191 [PMID: 36572501]
  46. JAMA. 2010 Apr 28;303(16):1610-6 [PMID: 20424251]
  47. BMJ Open. 2019 Mar 23;9(3):e025026 [PMID: 30904859]
  48. Scand Cardiovasc J. 2015 Jun;49(3):159-67 [PMID: 25919145]
  49. J Natl Cancer Inst. 2021 Aug 2;113(8):1065-1073 [PMID: 33484569]
  50. Am J Respir Crit Care Med. 2018 Jan 15;197(2):172-182 [PMID: 28977754]
  51. JAMA. 2014 Apr 9;311(14):1406-15 [PMID: 24682252]
  52. BMJ Open. 2022 Dec 8;12(12):e067263 [PMID: 36600392]

Grants

  1. ARCMOB2023010006185/Fondation ARC pour la recherche sur le cancer

MeSH Term

Humans
Male
Pulmonary Disease, Chronic Obstructive
Middle Aged
Female
Lung Neoplasms
Tomography, X-Ray Computed
Early Detection of Cancer
Cardiovascular Diseases
Aged
Smoking Cessation
Feasibility Studies
Spirometry
Smoking
Mass Screening
Logistic Models

Word Cloud

Created with Highcharts 10.0.0lungdiseasecancerscreeningobstructivelow-dose31diseasesCOPDCTassociatedparticipantsCACsfollow-upparticipationCVD12cardiovascularchronicpulmonaryLUMASCANCancercomputedtomographystudyfeasibilitycommunitypopulationcentralizedorganizationeventsmedian27%respectively4%43moderatesevere95%=BACKGROUND:LungprogramsconcernsmokersriskCVDsLUngScreeningMArkersSCANneraimedevaluateacceptabilitydeterminemarkersMETHODS:cohortenrolledmeetingNationalComprehensiveNetworkcriteriav12014organizedcancer-screeningprogramincludingscansspirometryevaluationscoronaryarterycalcificationssmokingcessationplaninclusion2yearstelephoneOutcomesrateproportionaffectedLogistic-regressionmodelsusedidentifyradiologicalfactorsRESULTS:20162019total302enrolled:61%menage588 years77%activesmoker11%diabetes38%hypertensiontakinglipid-loweringagentsInclusion1-year2-yearrates99%81%79%581 yearsscreeningsdetected9via78%localizedstageIV83unknown131warrantingcardiologyconsultationPreexistingmajoroddsratios98confidentinterval[CI]008827CI726CONCLUSION:demonstratedcombinedenabledhighcoordinationhealthcarepractitionersBeyondopportunityearlydetection

Similar Articles

Cited By